Psoriasis Clinical Trials in Philadelphia

Showing 61-80 of 227 trials

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

NCT05642182

The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.

Psoriasis

SFA Therapeutics90 participantsStarted Mar 2022

Pompano Beach, Florida, United States • Fargo, North Dakota, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

Psoriasis

Amgen595 participantsStarted Mar 2019

Birmingham, Alabama, United States • Fort Smith, Arkansas, United States • Rogers, Arkansas, United States +61 more locations

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Psoriasis Trials in Other Cities

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Validation of Handheld Ultrasound Devices in Rheumatology

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

Other Conditions in Philadelphia